FDA Breaks 30-Year Treatment Droughts With Landmark Approvals for Kidney Disease and Rare Genetic Condition

The FDA approved finerenone (Kerendia) for adults with type 1 diabetes-associated chronic kidney disease this week—the first new treatment option for this population in more than 30 years, addressing a condition that affects roughly 30% of type 1 diabetes patients and remains a leading cause of death in that group.

Plain English

Imagine being told in 1994 that there was no new drug on the horizon for your kidney disease. That's the reality type 1 diabetes patients have faced...